Lassa Fever Clinical Course and Prognostic Factors in Nigeria

Active, not recruitingOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

April 5, 2018

Primary Completion Date

April 30, 2023

Study Completion Date

December 31, 2025

Conditions
Lassa FeverLassa Virus InfectionPregnancy ComplicationsAcute Kidney InjuryAcute Kidney FailureComa
Interventions
OTHER

Non interventional research

Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.

Trial Locations (2)

Unknown

Alex Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki

PMB 1053

Owo Federal Medical Centre (Owo FMC), Owo

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

University of Oxford

OTHER

collaborator

Irrua Specialist Teaching Hospital

OTHER

collaborator

Bernhard Nocht Institute for Tropical Medicine

OTHER_GOV

collaborator

University Hospital, Bordeaux

OTHER

collaborator

University of Bordeaux

OTHER

collaborator

PACCI Program

OTHER

collaborator

Institut de Recherche pour le Developpement

OTHER_GOV

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

collaborator

Federal Medical Centre, Owo

INDUSTRY

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Alliance for International Medical Action

OTHER